Suppr超能文献

用降血脂药物普罗布考、氯贝丁酯和非诺贝特治疗后大鼠肝细胞的超微结构比较研究。

Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.

作者信息

Barnard S D, Molello J A, Caldwell W J, LeBeau J E

出版信息

J Toxicol Environ Health. 1980 May;6(3):547-57. doi: 10.1080/15287398009529872.

Abstract

Experimental findings are reported for two similarly conducted studies. One was designed to compared rat liver cell ultrastructure during and after 91 d of dosing with probucol, a hypocholesterolemic agent, and clofibrate, a hypolipidemic drug known to elicit marked alteration of rat hepatocellular morphology. The second was designed to similarly assess male rats after 28 d of treatment with the hypolipidemic agent fenofibrate. Diet mixes for these studies were prepared to attain dosage levels of approximately 500 mg/kg . d for probucol, 250 mg/kg . d for clofibrate, and 100 mg/kg . d for fenofibrate. Control rats were given untreated basal ration. Weekly adjustments in dietary concentrations were made in accordance with group mean food consumption and body weight changes. Probucol and clofibrate treatments produced statistically significant reductions in mean serum cholesterol levels of both sexes after 28 and 91 d of dosing. Only male rats were given fenofibrate, and they exhibited statistically significant cholesterol reductions after 28 d. Clofibrate and fenofibrate administration resulted in marked increases in liver weight/body weight ratios. Probucol had no statistically significant effects on liver weight/body weight ratios after 28 and 91 consecutive days of treatment. Light microscopy of liver sections stained with hematoxylin and eosin revealed an abnormal amount of cytoplasmic granularity within hepatocytes from rats given clofibrate and fenofibrate. The granules were identified by electron microscopy and cytochemistry as enlarged, proliferated peroxisomes--a known rat hepatocellular response to treatment with many hypolipidemic drugs. In addition, ultrastructural cytochemistry suggested reduced amounts of catalase in individual peroxisomes after clofibrate and fenofibrate dosing. Liver tissue from rats given probucol showed no abnormal cytoplasmic granularity and, ultrastructurally, no peroxisomal changes. Liver tissues from probucol-treated rats revealed features similar to those encountered in tissues from untreated control animals. It was concluded that the hypocholesterolemic response elicited by probucol treatment does not involve significant changes in rat liver cell morphology.

摘要

报告了两项类似实验研究的结果。一项研究旨在比较大鼠在服用降胆固醇药物普罗布考和已知会引起大鼠肝细胞形态显著改变的降血脂药物氯贝丁酯91天期间及之后的肝细胞超微结构。第二项研究旨在以类似方式评估雄性大鼠在服用降血脂药物非诺贝特28天后的情况。这些研究的饮食混合物制备成使普罗布考的剂量水平约为500毫克/千克·天,氯贝丁酯为250毫克/千克·天,非诺贝特为100毫克/千克·天。对照大鼠给予未处理的基础日粮。根据各组平均食物消耗量和体重变化每周调整日粮浓度。给药28天和91天后,普罗布考和氯贝丁酯治疗使两性的平均血清胆固醇水平出现统计学显著降低。仅雄性大鼠给予非诺贝特,给药28天后它们的胆固醇降低具有统计学显著性。给予氯贝丁酯和非诺贝特导致肝重/体重比显著增加。连续治疗28天和91天后,普罗布考对肝重/体重比无统计学显著影响。用苏木精和伊红染色的肝脏切片的光学显微镜检查显示,给予氯贝丁酯和非诺贝特的大鼠肝细胞内细胞质颗粒异常增多。通过电子显微镜和细胞化学鉴定,这些颗粒为增大、增殖的过氧化物酶体,这是大鼠肝细胞对许多降血脂药物治疗的已知反应。此外,超微结构细胞化学表明,给予氯贝丁酯和非诺贝特后,单个过氧化物酶体中的过氧化氢酶含量减少。给予普罗布考的大鼠肝脏组织未显示异常的细胞质颗粒,超微结构上也无过氧化物酶体变化。普罗布考治疗的大鼠肝脏组织显示出与未处理对照动物组织相似的特征。得出的结论是,普罗布考治疗引起的降胆固醇反应不涉及大鼠肝细胞形态的显著变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验